Editorial: Phage Therapy: Past, Present and Future

Editorial Note: Past Report and Future Direction for Iranian Journal of Management Studies

Construction of Human Recombinant ScFv Phage Libraries from the Advanced Stages of Breast Carcinoma Patients

Advances in the field of antibody engineering, and the emergence of powerful screening technology such as filamentous phage display allowed to generate fully human antibodies with high affinities against virtually any desired target from immune or even naIve human repertoires. As a result, the immunogenicity problems related to applications of nonhuman based recombinant antibodies as therapeuti...

Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases

Antimicrobial resistance is considered to be one of the greatest challenges of medicine and our civilization. Lack of progress in developing new anti-bacterial agents has greatly revived interest in using phage therapy to combat antibiotic-resistant infections. Although a number of clinical trials are underway and more are planned, the realistic perspective of registration of phage preparations...

Formation of therapeutic phage cocktail and endolysin to highly multi-drug resistant Acinetobacter baumannii: in vitro and in vivo study

Objective(s): Phage therapy is a potential alternative treatment for infections caused by Acinetobacter baumannii, a significant nosocomial pathogen, which has evolved resistance to almost all conventional antimicrobial drugs in poor hygiene and conflicts areas such as Iraq. Materials and Methods: Bacteriophages were isolated to highly resistant isolates of A. baumannii to form therapeutic phag...

Phage in therapy and Prophylaxis History and Future Prospects

bacteriophages are well known in the biopharmaceutical industry, mainly due to their destructive impact on productivity of bacterialbased fermentations necessary for obtaining the product. however, it seems that their positive role may soon dominate their rather grim reputation in the biopharmaceutical industry. in this short editorial the reasons for the failure to fulfill the high hopes that ...